TOCCASTAR trial meets primary safety and efficacy endpoints at Heart Rhythm 2014


St Jude Medical has announced results of the TOCCASTAR clinical trial at Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions in San Francisco, USA. Results from the first prospective, randomised study of contact-force ablation technology for the treatment of paroxysmal atrial fibrillation met primary endpoints and supplement the growing body of evidence that supports the safety and effectiveness of contact-force ablation technology.

“The findings from the TOCCASTAR trial further demonstrate the strong safety and efficacy profile of the TactiCath irrigated ablation catheter for the treatment of atrial fibrillation,” says Vivek Reddy, director of electrophysiology at Mount Sinai Hospital, New York, USA. “The results of this study have significant clinical relevance for optimal cardiac ablation therapy and provide compelling evidence that contact-force ablation procedures are effective in treating paroxysmal atrial fibrillation.”

The TOCCASTAR study is a multicentre, non-inferiority study evaluating 300 patients in the US and Europe. The investigational device exemption (IDE) clinical trial, which followed device performance and assessed patient outcomes through 12 months of follow-up, met its primary safety and effectiveness endpoints. Results demonstrated that the TactiCath irrigated ablation catheter exceeded the safety and efficacy non-inferiority benchmarks set forth in the trial by 5.9% and 4.3%, respectively, based on a 95% confidence interval. In addition, approximately 75.9% of the patients that were treated optimally with contact-force ablation therapy via the TactiCath catheter were free from paroxysmal atrial fibrillation at the end of the 12 month follow-up period, compared to 58.1% of patients who did not receive 10 grams or more of force. Through previous studies, including TOCCATA, EFFICAS I and EFFICAS II, optimal contact-force parameters for the TactiCath catheter has been defined as 10 grams of force or more during ablation procedures.

“Results from the TOCCASTAR study represent an important step forward in contact-force ablation technologies,” says Srijoy Mahapatra, vice president of medical and scientific affairs, global clinical affairs at St Jude Medical. “We are confident our large and growing body of clinical evidence demonstrates that the use of contact-force ablation safely reduces the rate of atrial fibrillation recurrence and we look forward to making this important technology available to electrophysiologists in the USA.”

The TactiCath irrigated ablation catheter is designed to give physicians a real-time, objective measure of the force applied to the heart wall during a catheter ablation procedure. Without contact-force data, physicians must estimate the amount of force applied to the heart wall during an ablation. If too little force is applied, there is a risk of incomplete lesion formation that could result in atrial fibrillation recurrence, potentially requiring additional treatments. If too much force is applied, there is a risk of tissue injury, which can lead to serious procedure-related complications.

Data that are produced by the TactiCath irrigated ablation catheter is displayed on the EnSite Velocity system, a cardiac mapping and navigation system via the EnSite contact force module. The EnSite contact software module, which recently received CE mark approval, seamlessly integrates contact-force ablation technology and 3-D mapping and navigation capabilities.

The study has been conducted to gather data in support of US FDA approval and is the basis for the company’s premarket approval (PMA) submission that has been filed with the FDA. TactiCath has received CE mark approval and is commercially available in Europe. In the United States, TactiCath is available for investigational use only. The EnSite Contact Force Module is not approved for use in the USA.

(Visited 13 times, 1 visits today)